Cann GroupASX:CAN Return-on-Tangible-Asset is 78.56% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 1,003 Drug Manufacturers companies, Cann Group ranks better than 94.42% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Cann Group's annualizedNet Income for the quarter that ended in Dec. 2025 was A$52.76 Mil. Cann Group's average total tangible assets for the quarter that ended in Dec. 2025 was A$67.16 Mil. Therefore, Cann Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 78.56%.
The historical rank and industry rank for Cann Group's Return-on-Tangible-Asset or its related term are showing as below:
ASX:CAN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -46.17 Med: -22.25 Max: 20.16
Current: 20.16
During the past 9 years, Cann Group's highest Return-on-Tangible-Asset was 20.16%. The lowest was -46.17%. And the median was -22.25%.
ASX:CAN's Return-on-Tangible-Asset is ranked better than 94.42% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs ASX:CAN: 20.16
Cann Group (ASX:CAN) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Cann Group Return-on-Tangible-Asset Related Terms
Cann Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Cann Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CAN vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Cann Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 78.56% mean?
Cann Group (ASX:CAN) has a Return-on-Tangible-Asset of 78.56% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cann Group and its competitors. According to the industry distribution chart, Cann Group ranks #56 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Cann Group's Return-on-Tangible-Asset too high?
Cann Group's current Return-on-Tangible-Asset is 78.56%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. Cann Group's value of 78.56% is 2394% above this industry median. Based on the distribution chart, Cann Group ranks #56 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Cann Group's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #56 out of 1003 companies for Return-on-Tangible-Asset. This places Cann Group in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. Cann Group's value of 78.56% is 2394% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current Return-on-Tangible-Asset of 78.56% is 2394% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Cann Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current Return-on-Tangible-Asset is 78.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 77.5% below its estimated fair value. The current Return-on-Tangible-Asset is 78.56% and 2394% above the Drug Manufacturers industry median of 3.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current Return-on-Tangible-Asset is 78.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 